Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential-Reference-Cited by-同舟云学术

Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential

Published:2022-08 Issue: Volume:236 Page:108106
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Ceci Claudia,Lacal Pedro Miguel,Graziani Grazia

Funder

Regione Lazio

Ministero della Salute

Banca d'Italia

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference395 articles.

1. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001;Abrahams;Oncotarget,2018

2. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity;Ackerman;Nat. Can.,2021

3. Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma;Adachi;Histopathology,2019

4. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma: Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells;Agathanggelou;Am. J. Pathol.,1995

5. A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD–56-positive multiple myeloma;Ailawadhi;Clin. Lymphoma Myeloma Leuk.,2019

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-11

2. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08

3. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer;Cancer Drug Resistance;2024-06-03

4. Antibody drug conjugates in the clinic;Bioengineering & Translational Medicine;2024-05-04

5. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?;Pharmacological Research;2024-05